Judy E. Garber, MD, PhD, FAACR
Judy E. Garber, MD, PhD, FAACR, Chief of the Division of Cancer Genetics and Prevention at the Dana-Farber Cancer Institute, will receive the Association of American Cancer Institute’s (AACI) Distinguished Scientist Award on October 20, during the 2021 AACI/Cancer Center Administrators Forum (CCAF) Annual Meeting. Due to the COVID-19 pandemic, the meeting will take place in a virtual format.
AACI is recognizing Dr. Garber, Professor of Medicine at Harvard Medical School, for her breakthrough research on the treatment of triple-negative or basal-like breast cancer. She is a member of the National Academy of Medicine, past member of the National Cancer Institute Board of Scientific Councilors and the American Society for Clinical Investigation, and Past President of the American Association for Cancer Research. She was appointed by President Obama to serve a 6-year term on the National Cancer Advisory Board, and in 2013, she was elected to the Institute of Medicine.
Influencing Both Prevention and Treatment
“The AACI board and its membership are honored to have this opportunity to recognize Dr. Garber’s scientific achievements,” said AACI President Caryn Lerman, PhD, Director of the University of Southern California Norris Comprehensive Cancer Center. “Her translational research has shaped national guidelines in cancer genetics and enhanced our ability to prevent cancer.”
Caryn Lerman, PhD
Dr. Garber’s recent investigations of germline and somatic genetic markers to predict response to targeted therapies in patients with breast cancer expand the field and are impacting clinical practices everywhere. Other therapies are being studied to prevent cancer in women with a heightened genetic risk for certain types of the disease.
Dr. Garber attended Yale School of Medicine, receiving her MD in 1981. She completed her residency in internal medicine and fellowship in hematology at Brigham and Women’s Hospital and her fellowship in medical oncology at the Dana-Farber Cancer Institute.
